- Home
- TLS vs MGNX Comparison
TLS vs MGNX Comparison
Compare TLS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- MGNX
- Stock Information
- Founded
- TLS 1969
- MGNX 2000
- Country
- TLS United States
- MGNX United States
- Employees
- TLS N/A
- MGNX N/A
- Industry
- TLS EDP Services
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- TLS Technology
- MGNX Health Care
- Exchange
- TLS Nasdaq
- MGNX Nasdaq
- Market Cap
- TLS 238.1M
- MGNX 257.3M
- IPO Year
- TLS 2020
- MGNX 2013
- Fundamental
- Price
- TLS $3.50
- MGNX $3.17
- Analyst Decision
- TLS Buy
- MGNX Hold
- Analyst Count
- TLS 6
- MGNX 10
- Target Price
- TLS $4.80
- MGNX $7.17
- AVG Volume (30 Days)
- TLS 454.9K
- MGNX 506.1K
- Earning Date
- TLS 11-12-2024
- MGNX 11-05-2024
- Dividend Yield
- TLS N/A
- MGNX N/A
- EPS Growth
- TLS N/A
- MGNX N/A
- EPS
- TLS N/A
- MGNX N/A
- Revenue
- TLS $122,959,000.00
- MGNX $141,329,000.00
- Revenue This Year
- TLS N/A
- MGNX $174.73
- Revenue Next Year
- TLS $38.31
- MGNX N/A
- P/E Ratio
- TLS N/A
- MGNX N/A
- Revenue Growth
- TLS N/A
- MGNX 16.68
- 52 Week Low
- TLS $1.89
- MGNX $2.95
- 52 Week High
- TLS $5.03
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- TLS 49.00
- MGNX 41.22
- Support Level
- TLS $3.38
- MGNX $3.10
- Resistance Level
- TLS $3.91
- MGNX $3.45
- Average True Range (ATR)
- TLS 0.22
- MGNX 0.20
- MACD
- TLS 0.01
- MGNX -0.01
- Stochastic Oscillator
- TLS 37.88
- MGNX 17.24
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).